ALETHIA BIOTHERAPEUTICS
Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression o... f which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.
ALETHIA BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2002-01-01
Address:
Montrรฉal, Quebec, Canada
Country:
Canada
Website Url:
http://www.alethiabio.com
Total Employee:
11+
Status:
Active
Contact:
514-858-7666
Email Addresses:
[email protected]
Total Funding:
20.28 M USD
Technology used in webpage:
SPF Google Font API Google Analytics WordPress Wordpress Plugins Microsoft Exchange Online Office 365 Mail AJAX Libraries API PHP Google Analytics Classic
Similar Organizations
Ablexis
Ablexis is a biotechnology company developing an innovative, next-generation platform for antibody drug discovery.
Aerpio Pharmaceuticals
Aerpio Pharmaceuticals is a biotechnology company that develops small molecules and monoclonal antibodies for vascular diseases treatment.
Biogen Idec
Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Enosi Life Sciences
Enosi Life Sciences is a drug research and development company providing therapeutics for autoimmune diseases and cancer.
Heron Therapeutics
Heron Therapeutics is a biotechnology firm specializing in polymer-based pharmaceuticals.
InterX
InterX, Inc. is a biotechnology startup revolutionizing biomolecular computation.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Neurotech
Neurotech is a biotechnology company developing sight-saving therapeutics for chronic retinal diseases.
NovelMed Therapeutics
NovelMed Therapeutics is a biotechnology company developing novel therapies for orphan and non-orphan diseases.
Oceana Therapeutics
Oceana Therapeutics is a global company committed to commercializing best-in-class therapeutics with a focus on colorectal,
Planet Biotechnology
Planet Biotechnology is a clinical-stage company that develops monoclonal antibody-based therapeutic and preventative products.
Protiva Biotherapeutics
Protiva Biotherapeutics is a biotechnology company developing nucleic acid based pharmaceutical products.
Rewrite Therapeutics
Rewrite Therapeutics is a private biotechnology company focused on advancing novel DNA writing technologies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Investissement Quebec
Investissement Quebec investment in Debt Financing - Alethia BioTherapeutics
GO Capital Fund
GO Capital Fund investment in Series B - Alethia BioTherapeutics
BDC Venture Capital
BDC Venture Capital investment in Series B - Alethia BioTherapeutics
AgeChem Venture Fund
AgeChem Venture Fund investment in Series B - Alethia BioTherapeutics
BDC Healthcare Venture
BDC Healthcare Venture investment in Series B - Alethia BioTherapeutics
GO Capital Fund
GO Capital Fund investment in Series A - Alethia BioTherapeutics
Epicenter Technology
Epicenter Technology investment in Series A - Alethia BioTherapeutics
AgeChem Venture Fund
AgeChem Venture Fund investment in Series A - Alethia BioTherapeutics
BDC Venture Capital
BDC Venture Capital investment in Series A - Alethia BioTherapeutics
GO Capital Fund
GO Capital Fund investment in Seed Round - Alethia BioTherapeutics
Official Site Inspections
http://www.alethiabio.com
- Host name: vux.netsolhost.com
- IP address: 206.188.192.186
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
More informations about "Alethia BioTherapeutics" on Search Engine
Alethia BioTherapeutics - Crunchbase Company Profile & Funding
Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer โฆSee details»
Management | Alethia Biotherapeutics
About Alethia. Corporate highlights; Management; Board of directors; Scientific Advisory Board; Research & Development. Therapeutic pipeline; Discovery platform; Products; โฆSee details»
Alethia Biotherapeutics Inc. | LinkedIn
Alethia Biotherapeutics Inc. is a biotechnology company based out of Montreal, QC, Canada. site. http://www.alethiabio.com. Industry. Biotechnology. Company size. 11 โฆSee details»
Alethia Biotherapeutics Inc. | BDC.ca
Alethia is developing innovative therapeutic approaches in areas of unmet medical needs, capitalizing on its capacity to identify and validate disease-specific targets for the โฆSee details»
Alethia Biotherapeutics | VentureRadar
Alethia is a privately held, Montreal-based biotechnology company created in 2002. Alethia develops monoclonal antibody therapeutics to novel clinically relevant targets โฆSee details»
Alethia BioTherapeutics - Funding, Financials, Valuation & Investors
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.See details»
Mario Filion - Co-Founder, Executive Vice President
Primary Organization. Alethia BioTherapeutics. Location Montréal, Quebec, Canada. Gender Male. LinkedIn View on LinkedIn. Mario Filion was involved in the creation of โฆSee details»
Alethia Biotherapeutics Closes a $4.7 Million Financing to โฆ
Nov 1, 2012 Alethia is a privately held, Montreal-based biotechnology company created in 2002. Alethia develops monoclonal antibody therapeutics to novel clinically relevant โฆSee details»
Alethia BioTherapeutics, Inc. Strengthens its Board of Directors
Dec 15, 2009 Alethia is a privately held, Montreal-based biotechnology company created in 2002. Alethia develops innovative therapeutic approaches in areas of unmet medical โฆSee details»
Alethia BioTherapeutics, Inc. Secures C$9.6 Million in Series A ...
Sep 7, 2010 Alethia BioTherapeutics, Inc. Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline | BioSpace.See details»
Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) โฆ
Feb 17, 2015 MONTREAL, QUEBEC-- (Marketwired - Feb 17, 2015) - Alethia Biotherapeutics Inc., a privately held biotechnology company, announced today that it โฆSee details»
Yves Cornellier - President and CEO @ Alethia BioTherapeutics ...
Yves Cornellier. Summary. Overview. CB Rank (Person) 170,572. Primary Job Title President and CEO. Primary Organization. Alethia BioTherapeutics. Location โฆSee details»
May 21, 2020 | Alethia Biotherapeutics
May 21, 2020. Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5. MONTREAL, May 21, 2020 โ โฆSee details»
Research programme: monoclonal antibody therapeutics - Alethia ...
Nov 4, 2017 Alethia BioTherapeutics is developing monoclonal antibodies generated against disease-specific targets for the treatment of bone resorption, ovarian cancer, โฆSee details»
Organization | Alethia Biotherapeutics - CDEK
Organization Overview. First Clinical Trial. 2015 NCT02412462. First Marketed Drug. None First NDA Approval. None ... Alethia Biotherapeutics | Alethia Biotherapeutics Inc. โฆSee details»
Alethia Biotherapeutics Announces Issuance of its Second โฆ
Aug 11, 2011 Alethia Biotherapeutics Announces Issuance of its Second Therapeutic Target Patent Stemming from its Proprietary Target Discovery PlatformSee details»
Alethia BioTherapeutics - Contacts, Employees, Board Members, โฆ
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.See details»
Sotevtamab - Alethia BioTherapeutics/International โฆ
Mar 14, 2024 Drug Profile. Sotevtamab - Alethia BioTherapeutics/International Biotechnology Center Generium. Alternative Names: 16B5; AB-16B5; AB-sCLU mAB; โฆSee details»